Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Total 13F shares
-
12,313,754
-
Share change
-
-1,549,642
-
Total reported value
-
$16,499,051
-
Put/Call ratio
-
100%
-
Price per share
-
$1.34
-
Number of holders
-
45
-
Value change
-
-$2,039,084
-
Number of buys
-
9
-
Number of sells
-
18
Institutional Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q3 2024
As of 30 Sep 2024,
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,313,754 shares.
The largest 10 holders included
Anson Funds Management LP, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Alphabet Inc., ADAR1 Capital Management, LLC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, Novo Holdings A/S, and Atlas Venture Life Science Advisors, LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.